Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy
Yujie Sun, Yanxia Guo, Xiaoqing Liu, Jinling Liu, Honglai Sun, Zhongying Li, Min Wen, Shengnan Jiang, Wenzhi Tan, Jin Zheng
Abstract
HCS1 strain manifests high prospects for cancer therapeutics and is a promising option for future clinical cancer immunotherapy.
Topics & Concepts
Oncolytic virusImmune systemCancerCancer researchCancer immunotherapyCancer cellCytotoxicityMedicineImmunotherapyIn vivoImmunosuppressionIn vitroSalmonellaImmunologyPharmacologyBiologyBacteriaInternal medicineBiotechnologyGeneticsBiochemistryCancer Research and TreatmentsNanoplatforms for cancer theranosticsVirus-based gene therapy research